Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) does about 3.19M shares in volume on a normal day but saw 1713034 shares change hands in Monday trading. The company now has a market cap of 1.12B USD. Its current market price is $8.29, marking a decrease of -0.48% compared to the previous close of $8.33. The 52 week high reached by this stock is $20.48 whilst the lowest price level in 52 weeks is $4.07. The script in recent trading has seen the stock touch a high of $8.465 and a low of $8.14.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Aurinia Pharmaceuticals Inc. (AUPH) has a 20-day trading average at $6.80 and the current price is -59.51% off the 52-week high compared with 103.69% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.62 and its 200-day simple moving average is $8.43. If we look at the stock’s price movements over the week, volatility stands at 6.84%, which increases to 8.17% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.77 to suggest the stock is neutral.
8 analysts observing the Aurinia Pharmaceuticals Inc. (AUPH) stock have set the 12-month price targets for the company’s shares at between $5.18 and $15.00. The consensus objective for the share price is $12.50, suggesting that the stock has a potential upside of 33.68% over the period. The median price target is 36.23% away from the current levels at $13.00.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 5 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
Oppenheimer upgraded its price target at $33-$31.
The current price level is 25.22%, 49.04%, and -1.85% away from its SMA20, SMA50, and SMA200 respectively, with the AUPH price moving below the 50-day SMA on January 23. Aurinia Pharmaceuticals Inc. (AUPH) stock is down -9.00% over the week and 85.46% over the past month. Its price is 91.90% year-to-date and -54.02% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.25 below consensus estimates by -$0.03. The company’s next earnings report is expected on 05/17/2023, with forecasts estimating quarterly EPS at -$0.17 and -$0.83 for whole year. AUPH’s earnings per share are forecast to grow by 40.70% this year and 56.60% over next year. Expected sales for next quarter are $49.01 million, which analysts say will come at $136.21 million for the current fiscal year and next year at $231.36 million. In addition, estimates put the company’s current quarterly revenue at an average of $36.18 million.
Its 12-month price target is $13.00. To reach the target analysts have set, the stock logically needs to grow 33.68 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.18, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $15.00.
Outstanding shares total 141.86M with insiders holding 6.50% of the shares and institutional holders owning 36.95% of the company’s common stock. The company has a return on investment of -37.90% and return on equity of -26.00%. The beta has a value of 0.92. Price to book ratio is 2.78 and price to sales ratio is 8.69.
According to a U.S. Securities and Exchange Commission filing, iShares Russell 2000 ETF has reduced its position in Aurinia Pharmaceuticals Inc. (AUPH) to 3,008,566 shares, mirroring a recent drop by -1.03%. iShares Russell 2000 ETF dumped 31415.0 shares of Aurinia Pharmaceuticals Inc. common stock bringing its total worth to about $13.0 million at the end of recent close, SEC documents show. iShares Russell 2000 ETF isn’t the only investment manager who changed stakes and is followed by iShares Russell 2000 Growth ETF, which added 2510.0 shares to end up with 1,122,074 shares worth $4.85 million. iShares Biotechnology ETF raise their holdings by 0.38% in the company over the course of the most recent quarter. It now holds a 0.76% position in Aurinia Pharmaceuticals Inc. thanks to 1.08 million shares amounting to $4.68 million.
